Description: Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease.
Home Page: www.tricida.com
TCDA Technical Analysis
7000 Shoreline Court
South San Francisco,
CA
94080
United States
Phone:
415 429 7800
Officers
| Name | Title |
|---|---|
| Dr. Gerrit Klaerner Ph.D. | Founder, Pres, CEO & Exec. Director |
| Mr. Geoffrey M. Parker | COO, CFO & Exec. VP |
| Mr. Robert L. McKague J.D. | Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer |
| Dr. Dawn Parsell Ph.D. | Exec. VP of Clinical Devel. |
| Ms. Annie Yoshiyama | VP of Fin. & Chief Accounting Officer |
| Jackie Cossmon | VP of Investor Relations & Communications |
| Mr. Edward J. Hejlek Esq., J.D. | Exec. VP of Intellectual Property |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2323.7769 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2018-06-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 57 |